Loading...
XOSLULTI
Market cap7mUSD
Dec 23, Last price  
2.44NOK
1D
-4.31%
1Q
34.07%
IPO
-92.31%
Name

Ultimovacs ASA

Chart & Performance

D1W1MN
XOSL:ULTI chart
P/E
P/S
EPS
Div Yield, %
0.00%
Shrs. gr., 5y
16.51%
Rev. gr., 5y
%
Revenues
0k
Net income
-189m
L+28.82%
-28,776,000-32,269,000-53,904,000-55,851,000-116,718,000-166,757,000-146,901,000-189,239,000
CFO
-190m
L+13.20%
-31,099,000-27,225,000-50,389,000-62,989,000-108,223,000-125,828,000-167,695,000-189,827,000
Earnings
Feb 13, 2025

Profile

Ultimovacs ASA, a pharmaceutical company, develops immunotherapies for cancers. Its lead product candidate is UV1, a peptide-based vaccine that induces T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
IPO date
Jun 03, 2019
Employees
24
Domiciled in
NO
Incorporated in
NO

Valuation

Title
NOK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
126,602
107,069
104,499
Unusual Expense (Income)
NOPBT
(126,602)
(107,069)
(104,499)
NOPBT Margin
Operating Taxes
(20,891)
2,035
Tax Rate
NOPAT
(126,602)
(86,178)
(106,534)
Net income
(189,239)
28.82%
(146,901)
-11.91%
(166,757)
42.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
300
5,484
272,864
BB yield
-0.01%
-0.15%
-7.47%
Debt
Debt current
1,827
1,767
1,628
Long-term debt
5,599
9,193
2,542
Deferred revenue
Other long-term liabilities
(1,000)
Net debt
(259,133)
(414,349)
(569,998)
Cash flow
Cash from operating activities
(189,827)
(167,695)
(125,828)
CAPEX
(25)
(195)
(85)
Cash from investing activities
14,034
8,691
2,977
Cash from financing activities
(1,847)
3,577
259,957
FCF
(124,613)
(89,680)
(104,690)
Balance
Cash
266,559
425,309
574,168
Long term investments
Excess cash
266,559
425,309
574,168
Stockholders' equity
(797,216)
(626,957)
(477,689)
Invested Capital
1,080,320
1,081,788
1,072,926
ROIC
ROCE
EV
Common stock shares outstanding
34,398
34,247
32,373
Price
122.80
11.64%
110.00
-2.48%
112.80
41.00%
Market cap
4,224,074
12.13%
3,767,170
3.16%
3,651,674
50.85%
EV
3,964,941
3,352,821
3,081,676
EBITDA
(123,834)
(104,421)
(101,796)
EV/EBITDA
Interest
382
15,839
333
Interest/NOPBT